4/30/2014 | HYLM | SkyePharma calls remaining 61/2% bonds due 2024 after securing go-ahead
|
3/31/2014 | HYLM | SkyePharma tenders, seeks consents for £61 million 61/2% bonds due 2024
|
9/25/2012 | CVDDLM | SkyePharma gets holder approval to amend convertibles, delay put dates
|
8/23/2012 | CVDDLM | SkyePharma seeks consents to push back put dates for convertible notes
|
9/25/2008 | CV | SkyePharma holders approve changes to convertibles due 2024 at meeting
|
9/23/2008 | CV | SkyePharma gets consents needed to amend conversion prices, put dates of convertibles due 2024, 2025
|
9/2/2008 | CV | SkyePharma looks to amend conversion price, put dates of convertibles due 2024, 2025
|
11/10/2006 | BT | Jefferies puts SkyePharma at buy
|
9/29/2006 | BT | SkyePharma at buy by Jefferies
|
9/28/2006 | BT | SkyePharma posts net loss of £26.4 million for first half of year
|
9/6/2006 | BT | SkyePharma, Mundipharma to market Flutiform for asthma in Europe
|
8/11/2006 | BT | Market Commentary: Encysive spikes, slips to red; SkyePharma still looking for buyer; Pharmacyclics sinks
|
8/11/2006 | BT | SkyePharma: No 'fundamental reason' for decline in share price; expects to sell injectables business by year end
|
6/30/2006 | BT | SkyePharma reacquires European rights for DepoBupivacaine from Mundipharma
|
6/23/2006 | BT | SkyePharma at buy by Jefferies
|
6/21/2006 | BT | SkyePharma hopes to increase royalties by assuming more risks
|
6/12/2006 | BTPP | SkyePharma reduces conversion price on £20 million in convertible bonds
|
5/22/2006 | BT | SkyePharma, First Horizon to develop controlled-release version of Sular for hypertension
|
5/8/2006 | BT | SkyePharma, Kos sign deal for marketing, distribution of asthma drug Flutiform in United States
|
4/28/2006 | BT | SkyePharma's DepoDur for pain approved by U.K. agency
|
4/21/2006 | BT | SkyePharma, Endo to stop development of Propofol anesthetic
|
4/19/2006 | BT | SkyePharma says revenue falls 18%, net loss jumps 174% in 2005
|
4/5/2006 | BT | Jefferies puts SkyePharma at buy
|
3/14/2006 | BT | SkyePharma agrees with major shareholders to appoint non-executive directors
|
3/9/2006 | BT | SkyePharma shareholders shoot down appointment of new director
|
3/2/2006 | BT | SkyePharma extraordinary general meeting set for March 9
|
2/13/2006 | BT | SkyePharma director Ian Gowrie-Smith retires from board
|
2/6/2006 | BT | SkyePharma appoints chief executive, chief operating officer
|
2/2/2006 | BT | SkyePharma to dump injectable business interests, hires new chairman
|
1/30/2006 | BT | SkyePharma shareholders call for meeting to install new director
|
1/23/2006 | BT | Market Commentary: Genitope shares fall nearly 10% on follow-on plans; Arena slides; SkyePharma up; MannKind drops
|
1/23/2006 | BT | SkyePharma's chairman resigns
|
1/20/2006 | BT | SkyePharma shareholders call for replacement of director
|
1/11/2006 | BT | SkyePharma says doesn't have buyer for company as whole, may sell assets
|
12/8/2005 | BT | SkyePharma opens data room for bidders, has possible buyers for all or part of company
|
11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
11/14/2005 | BT | Market Commentary: OSI, Eyetech tie knot; Genentech hits new high; SkyePharma soars on buyout interest; Onyx launches
|
11/14/2005 | BT | SkyePharma appoints Lehman Brothers as financial adviser for review of options
|
11/3/2005 | BT | SkyePharma sees 83% response to rights offering; CSFB places remaining shares
|
11/1/2005 | BT | Maruho pays SkyePharma $18 million to sell DepBupivacaine in Japan
|
9/30/2005 | BT | Market Commentary: Predix IPO price range emerges; Genomic, Avalon, Sunesis a mix; Progenics up; BioDelivery slides
|
9/28/2005 | BT | Market Commentary: Panacos, SkyePharma add to deal slate; Incyte, Endo drop on news; Electro-Optic rejigs talk, syndicate
|
9/28/2005 | BT | SkyePharma plans rights offering for £35 million to fund asthma drug phase III trials
|
5/31/2005 | PP | New Issue: SkyePharma plans £20 million private placement of convertibles
|
7/8/2004 | CV | SkyePharma says £49.9 million 6% convertibles tendered
|
7/1/2004 | CV | SkyePharma offers convertibles due 2024 for existing convertibles due 2005
|